Shots:

• The P-III EMPOWER-Lung 3 trial evaluates Libtayo (350mg- IV- q3w for 108wks.) + platinum-doublet CT (q3w for 4 cycles) vs platinum-doublet CT alone in a ratio (2:1) in 466 patients with metastatic or LA tumors with either sq./nsq. histology across all PD-L1 expression levels
• The results demonstrated an improvement in OS (22 vs 13mos.)- 29% reduction in risk of death with no new safety signals were observed in the IDMC analysis
• The companies plan for regulatory submissions in the US and EU based on these results. Libtayo is a fully human mAb targeting the immune checkpoint receptor PD-1 on T-cells

| Ref: Globe Newswire | Image: France 24